Top Ten Warning Letter Observations about the Pharmaceutical Quality Unit

Top Ten Warning Letter Observations about the Pharmaceutical Quality Unit

August 17th, 2011 // 12:57 pm @

The responsibilities of the Pharmaceutical Quality Unit are defined in the CGMPs and practices clarified in guidance documents.

Just as it is with any legal matter, case histories help us understand how the law is applied in specific situations. That’s the reason it is a good practice to regularly review Warning Letters on the FDA website.

New Webinar Oct. 12 – Avoid FDA Recall Nightmares – Update from FDA Branch Chief for CDRH Recalls

Here’s my condensed list of issues the FDA has had with the Quality Unit as seen in Warning letter observations.

This is the list you don’t want to be on.

1. QU failed to establish a system to ensure that…[fill in the blank for anything that went wrong]

2. QU failed to document the responsibilities applicable to the quality control unit in procedures, and fully perform these responsibilities.

3. The personnel performing laboratory tests… were not trained.

4. QU failed to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products.

5. QU failed to fully perform and/or document the review of batch production records to determine compliance with all established, approved written procedures before a batch is released or distributed.

6. QU failed to ensure that all tests are in conformance with the established specifications and that these are met prior to the release of drug products for distribution.

7. QU did not review production records to assure that no errors had occurred or, if errors had occurred, that they had been fully investigated, conclusions made and followed-up.

8. QU failed to investigate complaints involving the possible failure of a drug product to meet any of its specifications.

9. Failure to submit NDA-Field Alert Reports (FARs) within three (3) working days of receipt of information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug products

10. And my personal favorite…a designated QU has not been established.


Source


Subscribe Now

Testimonial

"ExpertBriefings.com always selects excellent speakers – some of the best I have ever heard. Their messages are direct, clear, timely, and relevant."

Anon A. Mouse

Featured Partner